World Health Organization Sounds Warning Over Acute Scarcity of Obesity Jabs
Less than one in 10 patients that would benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it publishes its initial guidance on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
Based on estimates, over two billion could be living with obesity by 2030 if no action is taken.
"Our latest guidance acknowledges that obesity is a lifelong illness that can be addressed with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to universal availability to the treatments that can assist patients in reducing considerable weight, says the body.
Weight-Loss Drug Supply Crisis
Even in the current best projected outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The recommendation encourages countries and companies to expand availability, by measures including licensing agreements.
A patent on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Work
These medications replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people consume fewer calories.
People commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Evidence points to users may see weight return a year later of stopping the treatment, because their typical hunger come back.
Being above a healthy weight elevates your likelihood for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight affects individuals in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.
